How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 759-766

  Scully, Marie ^a   Goodship, Tim ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Atypical haemolytic uraemic syndrome; Complement; Diagnosis; Thrombotic thrombocytopenic purpura; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; CREATININE; CYCLOSPORIN; DIACYLGLYCEROL KINASE; DIACYLGLYCEROL KINASE EPSILON; ECULIZUMAB; FIBRINOGEN; MENINGOCOCCUS VACCINE; OCTAPLAS; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADJUVANT THERAPY; BLOOD ANALYSIS; BLOODY DIARRHEA; C3 GENE; CARDIOVASCULAR DISEASE; CD46 GENE; CFB GENE; CFH GENE; CFI GENE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DGKE GENE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EARLY INTERVENTION; ENZYME ACTIVITY; FEVER; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MENINGOCOCCOSIS; MICROANGIOPATHY; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; PATIENT CARE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA TRANSFUSION; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REMISSION; RENAL REPLACEMENT THERAPY; REVIEW; THBD GENE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME; COMPLEMENT; DIAGNOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT;

ADAM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84896719422     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12718     Document Type: Review

References (43)

1. Ahmad, A., Aggarwal, A., Sharma, D., Dave, H.P., Kinsella, V., Rick, M.E. & Schechter, G.P. (2004) Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). American Journal of Hematology, 77, 171-176.
2. Bresin, E., Daina, E., Noris, M., Castelletti, F., Stefanov, R., Hill, P., Goodship, T.H. & Remuzzi, G. (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clinical Journal of the American Society of Nephrology, 1, 88-99.
3. Cataland, S.R., Jin, M., Ferketich, A.K., Kennedy, M.S., Kraut, E.H., George, J.N. & Wu, H.M. (2007a) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. British Journal of Haematology, 136, 146-149.
4. Cataland, S.R., Jin, M., Lin, S., Kennedy, M.S., Kraut, E.H., George, J.N. & Wu, H.M. (2007b) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. British Journal of Haematology, 139, 486-493.
5. Chemnitz, J., Draube, A., Scheid, C., Staib, P., Schulz, A., Diehl, V. & Sohngen, D. (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. American Journal of Hematology, 71, 105-108.
6. Coppo, P., Schwarzinger, M., Buffet, M., Wynckel, A., Clabault, K., Presne, C., Poullin, P., Malot, S., Vanhille, P., Azoulay, E., Galicier, L., Lemiale, V., Mira, J.P., Ridel, C., Rondeau, E., Pourrat, J., Girault, S., Bordessoule, D., Saheb, S., Ramakers, M., Hamidou, M., Vernant, J.P., Guidet, B., Wolf, M. & Veyradier, A. (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One, 5, e10208.
7. Fakhouri, F., Vernant, J.P., Veyradier, A., Wolf, M., Kaplanski, G., Binaut, R., Rieger, M., Scheiflinger, F., Poullin, P., Deroure, B., Delarue, R., Lesavre, P., Vanhille, P., Hermine, O., Remuzzi, G. & Grunfeld, J.P. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 106, 1932-1937.
8. Froissart, A., Buffet, M., Veyradier, A., Poullin, P., Provot, F., Malot, S., Schwarzinger, M., Galicier, L., Vanhille, P., Vernant, J., Bordessoule, D., Guidet, B., Azoulay, E., Rondeau, E., Mira, J., Wynckel, A., Clabault, K., Choukroun, G., Presne, C., Pourrat, J., Hamidou, M. & Coppo, P. (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine, 40, 104-111.
9. Gruppo, R.A. & Rother, R.P. (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. New England Journal of Medicine, 360, 544-546.
10. Gutterman, L.A., Kloster, B. & Tsai, H.M. (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells, Molecules, & Diseases, 28, 385-391.
11. Hart, D., Sayer, R., Miller, R., Edwards, S., Kelly, A., Baglin, T., Hunt, B., Benjamin, S., Patel, R., Machin, S. & Scully, M. (2011) Human immunodeficiency virus associated thrombotic thrombocytopenic purpura - favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. British Journal of Haematology, 153, 515-519.
12. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P. & Luzzatto, L. (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 355, 1233-1243.
13. Hosler, G.A., Cusumano, A.M. & Hutchins, G.M. (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Archives of Pathology and Laboratory Medicine, 127, 834-839.
14. Jasti, S., Coyle, T., Gentile, T., Rosales, L. & Poiesz, B. (2008) Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. Journal of Clinical Apheresis, 23, 151-156.
15. Kavanagh, D. & Goodship, T.H. (2011) Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology/The Education Program of the American Society of Hematology, 2011, 15-20.
16. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Cohen, D.R., Gregory, W.M. & Hillmen, P. (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 117, 6786-6792.
17. Kremer Hovinga, J.A., Vesely, S.K., Terrell, D.R., Lammle, B. & George, J.N. (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 115, 1500-1511.
18. Le, Q.M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., Cassuto, E., Loirat, C., Rondeau, E., Delahousse, M. & Fremeaux-Bacchi, V. (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. American Journal of Transplantation, 13, 663-675.
19. Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nurnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T. & Loirat, C. (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine, 368, 2169-2181.
20. Lemaire, M., Fremeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W.H., Le, Q.M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., Ji, W., Overton, J.D., Mane, S.M., Nurnberg, G., Altmuller, J., Thiele, H., Morin, D., Deschenes, G., Baudouin, V., Llanas, B., Collard, L., Majid, M.A., Simkova, E., Nurnberg, P., Rioux-Leclerc, N., Moeckel, G.W., Gubler, M.C., Hwa, J., Loirat, C. & Lifton, R.P. (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genetics, 45, 531-536.
21. Ling, H.T., Field, J.J. & Blinder, M.A. (2009) Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. American Journal of Hematology, 84, 418-421.
22. McDonald, V., Laffan, M., Benjamin, S., Bevan, D., Machin, S. & Scully, M.A. (2009) Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. British Journal of Haematology, 144, 430-433.
23. McDonald, V., Manns, K., MacKie, I.J., Machin, S.J. & Scully, M.A. (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 8, 1201-1208.
24. Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., Piras, R., Donadelli, R., Maranta, R., van der Meer, I., Conway, E.M., Zipfel, P.F., Goodship, T.H. & Remuzzi, G. (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clinical Journal of the American Society of Nephrology, 5, 1844-1859.
25. Nurnberger, J., Philipp, T., Witzke, O., Opazo, S.A., Vester, U., Baba, H.A., Kribben, A., Zimmerhackl, L.B., Janecke, A.R., Nagel, M. & Kirschfink, M. (2009) Eculizumab for atypical hemolytic-uremic syndrome. New England Journal of Medicine, 360, 542-544.
26. Ozaltin, F., Li, B., Rauhauser, A., An, S.W., Soylemezoglu, O., Gonul, I.I., Taskiran, E.Z., Ibsirlioglu, T., Korkmaz, E., Bilginer, Y., Duzova, A., Ozen, S., Topaloglu, R., Besbas, N., Ashraf, S., Du, Y., Liang, C., Chen, P., Lu, D., Vadnagara, K., Arbuckle, S., Lewis, D., Wakeland, B., Quigg, R.J., Ransom, R.F., Wakeland, E.K., Topham, M.K., Bazan, N.G., Mohan, C., Hildebrandt, F., Bakkaloglu, A., Huang, C.L. & Attanasio, M. (2013) DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. Journal of the American Society of Nephrology, 24, 377-384.
27. Peyvandi, F., Palla, R., Lotta, L.A., Mackie, I., Scully, M.A. & Machin, S.J. (2010) ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 8, 631-640.
28. Quaggin, S.E. (2013) DGKE and atypical HUS. Nature Genetics, 45, 475-476.
29. Reddy, P.S., Deauna-Limayo, D., Cook, J.D., Ganguly, S.S., Blecke, C., Bodensteiner, D.C., Skikne, B.S. & Sahud, M.A. (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Annals of Hematology, 84, 232-235.
30. de la Rubia, J., Moscardo, F., Gomez, M.J., Guardia, R., Rodriguez, P., Sebrango, A., Zamora, C., Deben, G., Goterris, R., Lopez, R., Pena, F., Pujol, M., Vidaller, A., del Rio-Garma, J. & Sanz, M.A. (2010) Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfusion and Apheresis Science, 43, 299-303.
31. Saland, J.M., Ruggenenti, P. & Remuzzi, G. (2009) Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology, 20, 940-949.
32. Sallah, S., Husain, A., Wan, J.Y. & Nguyen, N.P. (2004) Rituximab in patients with refractory thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2, 834-836.
33. Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451-461.
34. Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., Bevan, D., Mackie, I. & Machin, S. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology, 142, 819-826.
35. Scully, M., McDonald, V., Cavenagh, J., Hunt, B.J., Longair, I., Cohen, H. & Machin, S.J. (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746-1753.
36. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B. & Machin, S.J. (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 158, 323-335.
37. Studt, J.D., Bohm, M., Budde, U., Girma, J.P., Varadi, K. & Lammle, B. (2003) Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. Journal of Thrombosis and Haemostasis, 1, 1882-1887.
38. Taylor, C.M., Machin, S., Wigmore, S.J. & Goodship, T.H. (2010) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. British Journal of Haematology, 148, 37-47.
39. Tripodi, A., Chantarangkul, V., Bohm, M., Budde, U., Dong, J.F., Friedman, K.D., Galbusera, M., Girma, J.P., Moake, J., Rick, M.E., Studt, J.D., Turecek, P.L. & Mannucci, P.M. (2004) Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. Journal of Thrombosis and Haemostasis, 2, 1601-1609.
40. Westwood, J.P., Webster, H., McGuckin, S., McDonald, V., Machin, S.J. & Scully, M. (2013) Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. Journal of Thrombosis and Haemostasis, 11, 481-490.
41. Zheng, X., Pallera, A.M., Goodnough, L.T., Sadler, J.E. & Blinder, M.A. (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Annals of Internal Medicine, 138, 105-108.
42. Zuber, J., Fakhouri, F., Roumenina, L.T., Loirat, C. & Fremeaux-Bacchi, V. (2012a) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 8, 643-657.
43. Zuber, J., Le, Q.M., Krid, S., Bertoye, C., Gueutin, V., Lahoche, A., Heyne, N., Ardissino, G., Chatelet, V., Noel, L.H., Hourmant, M., Niaudet, P., Fremeaux-Bacchi, V., Rondeau, E., Legendre, C. & Loirat, C. (2012b) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. American Journal of Transplantation, 12, 3337-3354.